Related Experiment Video
Updated: May 15, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to
Caijiu Deng1,2, Junming Huang3, Qian Yu4
1Department of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical University, No. 8 Fuyu Road East, Panyu, Guangzhou, 511400, Guangdong, People's Republic of China.
Background:
The efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment.
Case Description:
A 67-year-old male was referred to our hospital due to persistent abdominal pain for 3 months. Abdominal computed tomography showed a tumor with a diameter of 92 mm in the left liver with multiple intrahepatic metastases. Immunohistochemistry revealed that tumor cells were positive for CK7 and CK19, and negative for hepatocyte and CDX- 2. A pathological diagnosis of intrahepatic CCA was made. Since the patient declined standard chemotherapy, afatinib was administered as the first-line treatment. Upon disease progression, apatinib was introduced. Unfortunately, the patient ultimately succumbed to hepatic failure, with a total survival of 1.8 months.
Conclusion:
In this report, the CCA patient with EGFR exon 19 deletion was unresponsive to afatinib treatment. However, genetic testing may be still worthwhile for CCA to increase the possible treatment options.
Insights
This case study found that a cholangiocarcinoma patient with an EGFR exon 19 deletion did not respond to afatinib treatment. Genetic testing is recommended for cholangiocarcinoma patients to explore potential treatment options.
Area of Science:
- Oncology
- Genetics
Background:
- The effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in cholangiocarcinoma (CCA) remains unclear.
- This report details a case of a 67-year-old CCA patient with an EGFR exon 19 deletion treated with afatinib.
Purpose of the Study:
- To evaluate the efficacy of afatinib in a CCA patient with a specific EGFR mutation.
- To highlight the potential role of genetic testing in identifying treatment options for CCA.
Main Methods:
- A 67-year-old male diagnosed with intrahepatic cholangiocarcinoma (CCA) with liver metastases.
- The patient received afatinib as first-line treatment due to refusal of standard chemotherapy.
- Subsequent treatment with apatinib was administered upon disease progression.
Main Results:
- The patient exhibited no response to afatinib treatment.
- The patient experienced disease progression and ultimately succumbed to hepatic failure.
- Overall survival was limited to 1.8 months.
Conclusions:
- The CCA patient with an EGFR exon 19 deletion was unresponsive to afatinib.
- Genetic testing may be beneficial for cholangiocarcinoma patients to identify potential therapeutic targets and expand treatment choices.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
